CRBU vs. MLYS, SAGE, ARCT, STOK, ALLO, UPB, SNDL, PROK, KROS, and ALT
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Mineralys Therapeutics (MLYS), Sage Therapeutics (SAGE), Arcturus Therapeutics (ARCT), Stoke Therapeutics (STOK), Allogene Therapeutics (ALLO), Upstream Bio (UPB), SNDL (SNDL), ProKidney (PROK), Keros Therapeutics (KROS), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.
Caribou Biosciences vs.
Caribou Biosciences (NASDAQ:CRBU) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
Mineralys Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat Mineralys Therapeutics' return on equity.
In the previous week, Caribou Biosciences had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 5 mentions for Caribou Biosciences and 2 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.49 beat Caribou Biosciences' score of 0.26 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
Caribou Biosciences has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Caribou Biosciences received 8 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 60.98% of users gave Caribou Biosciences an outperform vote.
Caribou Biosciences presently has a consensus target price of $10.33, suggesting a potential upside of 865.73%. Mineralys Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 202.01%. Given Caribou Biosciences' higher possible upside, equities research analysts plainly believe Caribou Biosciences is more favorable than Mineralys Therapeutics.
Caribou Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Caribou Biosciences beats Mineralys Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CRBU) was last updated on 3/4/2025 by MarketBeat.com Staff
